Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis

Table 1 Baseline characteristics of RCTs included in this review

Trial	Trial design	NOAC	Proportion of included patients	Sample size, n		Mean age (years)		Number of female (%)		Mean CHADS₂ score		TTR	Number of TOE (%)		Ref.
Trial	Trial design	NOAC	Proportion of included patients	NOAC	VKA	NOAC	VKA	NOAC	VKA	NOAC	VKA		NOAC	VKA	Ref.
ARISTOLE subgroup	Post-hoc analysis of a double-blinded RCT	Apixaban	171 (31.7%)	265	275	67	67	72 (27%)	74 (27%)	1.8	1.9	59.0%	86 (32%)	85 (31%)	[32]
RE-LY subgroup	Post-hoc analysis of an open-label RCT	Dabigatran 110 mg BD	1183 (53.8%)	647	664	NR	NR	NR	NR	NR	NR	NR	168 (26%)	86 (13%)	[33]
RE-LY subgroup	Post-hoc analysis of an open-label RCT	Dabigatran 150 mg BD	1183 (53.8%)	672	664	NR	NR	NR	NR	NR	NR	NR	161 (24%)	86 (13%)	[33]
ENSURE-AF	Open-label RCT to determine events after CV	Edoxaban	415 (20.9%)	1095	1104	64	64	374 (34%)	382 (35%)	2.6	2.6	70.8%	589 (54%)	594 (54%)	[31]
X-VeRT	Open-label RCT to determine events after CV	Rivaroxaban	628 (41.8%)	1002	502	65	65	275 (27%)	135 (27%)	NR*	NR*	NR	410 (41%)	218 (43%)	[34]

ARISTOTLE apixaban for the prevention of stroke in subjects with atrial fibrillation trial, BD twice daily, CV cardioversion, ENSURE-AF the edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation study, NOAC non-vitamin K antagonist oral anticoagulants, NR not reported, NR* not reported as mean value, RCT randomised controlled trial, Ref. Reference, RE-LY randomised evaluation of long-term anticoagulation therapy trial, TOE transesophageal echocardiography, TTR time in therapeutic range, X-VeRT explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with non-valvular atrial fibrillation scheduled for cardioversion

ISSN: 2047-783X